Skip to content
Bristows
  • Expertise

    Core sectors

    • Life sciences
    • Technology
    • Brands

    Litigation & dispute resolution (Archive)

    • Advertising & marketing
    • Arbitration
    • Artificial intelligence
    • Charities and not-for-profit
    • Commercial & IP transactions
    • Competition advice & investigations
    • Competition litigation
    • Confidential information & trade secrets disputes
    • Corporate & financing
    • Cyber & data breaches

    Transactions

    • Data protection & privacy
    • Defamation & privacy disputes
    • Employment & immigration
    • Freedom to operate
    • IT & digital projects
    • IT disputes
    • Life sciences disputes
    • Life sciences regulatory
    • Litigation & dispute resolution
    • Merger control
    • Open source

    Regulatory & advisory

    • Outsourcing
    • Patent litigation
    • Real estate
    • SEP/FRAND disputes
    • Tax
    • Technology regulation
    • Telecommunications
    • Trade mark, designs & copyright disputes
    • Trade mark & design portfolio management
    • UPC
  • Viewpoint
    • Articles
    • Events
    • Latest news
    • Podcasts
    • Publications
  • People
  • Careers
    • Apprentices
    • Current opportunities
    • Diversity, Equality & Inclusion
    • Life at Bristows
    • Trainees
  • About us
    • Alumni
    • A reputation for firsts
    • Awards and recognitions
    • Compliance information
    • Corporate responsibility
    • GDPR
    • International horizon
    • Our locations
    • Our values
  • Contact
  1. Home
  2. On the Pulse
  3. How the CJEU has interpreted “protected” in the SPC regulation

How the CJEU has interpreted “protected” in the SPC regulation

21.04.2017

Bristows partner Brian Cordery and associate Steven Willis look at how the CJEU has approached Article 3(a) of the SPC Regulation.

Read full article on the Managing IP website.

Brian Cordery

Author

  • LinkedIn
image description

Credentials

Practice areas

    What others say

    • Full profile
    • Back to people results

    Share

    • Facebook
    • Twitter
    • LinkedIn

    Practices

    • Patent litigation
    Related news
    • Human embryo research: should we re-draw the line?
      09.11.2023
    • Is the end near for UKCA marks for medical devices?
      14.08.2023
    • The present and future of SESG for biopharmaceutical companies
      16.06.2023
    • UK MDR amending legislation heralds arrival of new medical device framework
      24.05.2023
    • DNA sequencing by synthesis patents held valid and infringed
      03.05.2023
    • Under the antitrust spotlight: (mis)use of patents in the pharma sector
      12.04.2023
    Back to articles
    • linkedin
    • youtube
    • instagram
    (SRA Number 591711)
    Bristows LLP
    London:

    100 Victoria Embankment
    London EC4Y 0DH
    T +44 20 7400 8000
    DX 269

    Brussels:

    Avenue des Arts 56 
    1000 Bruxelles 
    Belgium 
    T +32 2 808 7500 

    Dublin:

    18-20 Merrion St Upper
    Dublin 2 , D02 XH98
    Ireland
    T +353 1 270 7755

    RSS feeds
    • News and publications
    • Events and seminars
    Other links
    • Bristows Trainees site
    • Accessibility
    • Compliance information
    • Cookie policy
    • Modern slavery act
    • Terms of use
    2026 Bristows LLP Website by Itineris